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GABAA receptors are ligand gated ion channels that are
targeted by drugs with multiple therapeutic applications.
Most notably, such drugs include the benzodiazepines, the
hypnotic Z-drugs (zolpidem, zopiclone, and zaleplon), and
the barbiturates. The benzodiazepines rapidly achieved pre-
eminence as minor tranquilizers when they were introduced
in the 1960s but thereafter lost favour, in a story that
exempliﬁes how a “good drug can go bad” [1]. Nevertheless,
benzodiazepines remain a mainstay of psychopharmacology
but the decline in their public image is encapsulated by
the colourful comment of Gorman [2] who stated that
“Prescribing benzodiazepines is like watching pornography.
If you ask a person at random if he watches pornography,
he will vehemently deny it, but someone must be because
it is a billion dollar a year business. Similarly, if you ask
a physician if he prescribes Valium or Xanax or Ativan,
he or she will say of course not.... Yet, like pornography,
benzodiazepine prescriptions generate billions of dollars of
revenue around the world, so somebody must be prescribing
them”. Recently, there has been a resurgence of interest
in GABAA receptor pharmacology which has formed the
basis for the development of novel modulators of discrete
populations of this receptor family [3].
Over the last 25 years or so considerable advances
in the molecular biology of GABAA receptors have
identiﬁed multiple subtypes of GABAA receptor. Hence,
GABAA receptors are heteropentameric assemblies of pro-
teins derived from a family comprising 16 members
(a1–6, β1–3, γ1–3, δ, ε, θ, π).Despitetheenormousnumber
of theoretical pentameric combinations, thankfully only
around 20 conﬁgurations have been described in native
receptors [4]. A variety of approaches have been used
to develop a greater understanding of the roles of these
diﬀerent subtypes in the physiology and pathophysiology
of the CNS. These strategies include the generation of
transgenic mouse models that have been used to delineate
the functions of diﬀerent subtypes, and the identiﬁcation
of subtype-selective pharmacological compounds that have
formed the basis of hypotheses that subtype-selectivity can
lead to therapeutic selectivity (e.g., anxioselective drugs
without sedation). A combination of these strategies has
resulted in emerging scientiﬁc evidence for novel therapeutic
applications for subtype-selective drugs (e.g., in neuropathic
pain,autism,schizophrenia,Alzheimer’sdisease,andstroke),
and consistent with these various hypotheses clinical data
on subtype-selective drugs in human trials indicate a novel
pharmacology relative to known drugs targeting GABAA
receptors. In this special issue, the articles focus on various
aspects of the molecular genetics as well as preclinical and
clinical pharmacology of GABAA receptors.
S. Nickoll’s et al. in his paper focus on the novel
therapeutic opportunity aﬀorded by drugs that positively
modulate GABAA-α2/α3 receptors selectively as novel anal-
gesics without sedation, cognition impairment, or abuse.
Testing such compounds in animal models of inﬂammatory
and neuropathic pain, complemented by in vivo electro-
physiology, they highlight the need for suﬃcient eﬃcacy
at relevant subtypes of GABAA receptor in addition to
selectivity. C. Vinkers and B. Olivier explore mechanisms
underlying benzodiazepine tolerance and conclude that
no unifying underlying mechanisms can be discerned but
emphasize that since this is an important therapeutic issue2 Advances in Pharmacological Sciences
with respects to currently marketed GABAergic drugs, it is
an important area to investigate with respects to emerging
subtype selective compounds.
GABAA-α5 and GABAA-δ receptors are located extrasy-
naptically, mediate tonic inhibitory neurotransmission in
the CNS, and have diﬀerent biophysical, physiological,
and pharmacological properties relative to GABAA-α1/α2/α3
receptors which are predominantly synaptically located. J.
Braudeau et al. focus on selective negative modulators
of GABAA-α5 receptors as a unique cognition enhancing
strategy in Down’s syndrome (DS), by demonstrating that
the selective compound α5IA induces gene expression (c-
fos and Arc) and rescues impaired gene expression in the
Ts65Dn mouse model of DS. The compound α5IA has
already shown evidence of cognition enhancement in man.
Currently, Roche pharmaceuticals is assessing a compound
(RG1662) in Down’s syndrome, and by extension the
relevance of this line of research in potentially reducing
cognitive burden in Alzheimer’s disease is clear. A. Clarkson
reviews the complex role of GABAA receptors in cerebral
ischaemia/stroke, suggesting that in an animal model of
stroke, treatment with the α5-selective negative allosteric
modulator L-655708 can enhance functional recovery when
given after a delay but not, interestingly, when given at
the time of stroke. The assumption is that the attenuation
of extrasynaptic GABAergic function can be beneﬁcial by
counteracting an increase in tonic inhibition that results
from increased GABA concentrations in the peri-infarct
region. Consequently, therapeutic strategies based upon a
disinhibition of GABAA-α5 or GABAA-δ receptors may aid
functional recovery in vivo.
A. C. Errington et al. suggest negative modulators of
GABAA-δ r e c e p t o r sa san o v e lt r e a t m e n to p t i o nf o ra b s e n c e
epilepsy given that enhanced GABAergic function has been
demonstrated in animal models of absence epilepsy, and
that compounds enhancing GABAA function can engender
absence seizures. Certainly this suggestion is contrary to
the classical approach of treating seizures by increasing
inhibitory neurotransmission, but the authors elegantly
demonstrate the relevance of key thalamocortical circuits in
generating EEG signatures common to animals and man
and the high expression and relevance of a α4β2δ receptor
population in this circuit. M. W. Hulin et al. focus on
literature implicating GABAA receptors and neurosteroids in
mediating actions of alcohol. They describe the neurosteroid
dehydroepiandrosterone (DHEA) which decreases alcohol
intake in rats and broadly behaves as a negative modulator of
GABAA receptors, although genomic eﬀects of this molecule
complicate matters. Nonetheless, the authors emphasize
the potential role of GABAA-δ receptors in mediating the
eﬀects of DHEA in reducing alcohol intake; albeit this is a
controversial area.
X. Chen et al. use a comparative pharmacology approach
in human volunteers to demonstrate that subtype-selective
GABAA drugs engender pharmacodynamic eﬀects that only
partly overlap with those of benzodiazepines. For example,
the GABAA-α2/α3 selective drug TPA023 induces impair-
mentofsaccadicpeakvelocitybutdoesnotinducebodysway
orimpairattentioninvolunteers.Thenovelpharmacological
proﬁle of subtype selective compounds in man mirrors
preclinicaldatausingtransgenicmousemodelsandsubtype-
selective tools, indicating that molecular neuroscience can be
translated to the clinic and guide drug development.
The paper by B. H. Bentzen and M. Grunnet gives
some insight into the drug development of new chemical
entities, speciﬁcally focusing on cardiovascular (CV) safety.
Clearly many benzodiazepines were registered for clinical
use in a regulatory environment considerably diﬀerent from
today’s. Therefore, in developing novel subtype-selective
modulators, assumptions cannot be made in terms of safety
and toxicology. These authors use anaesthetized animals
and isolated hearts to emphasize that the CV eﬀects of
benzodiazepines are highly dependent on the conscious state
of the animal, with implications for CV assessment of future
novel GABAergic molecules.
Given the wide-spread therapeutic success of GABAergic
drugs across a variety of indications and an emerging
understanding of the pharmacology of subtype-selective
drugspreclinicallyandclinically,GABAA receptorsareclearly
ahighlydruggabletargetclassforwhichpreclinicaltoclinical
transition/translation strategies exist—desirable qualities in
today’s highly complex drug development and regulatory
environment. The articles in this special issue give a snap-
shot of the diverse range of topics being explored regard-
ing the therapeutic utility of selectively targeting GABAA
receptors, providing a ground base of understanding for
potentially important drugs of the future.
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